Q2 2025 Resmed Inc Earnings Call Transcript

Jan 30, 2025 / 09:30PM GMT
Release Date Price: $21.7

Key Points

Positve
  • ResMed Inc (RMD) reported a strong quarter with a 10% increase in global revenue, driven by consistent contributions across its sleep health, breathing health, and residential care software portfolio.
  • The company achieved a 230 basis point expansion in non-GAAP gross margin to 59.2%, reflecting improved operating efficiencies.
  • ResMed Inc (RMD) saw double-digit growth in its masks and accessories business, supported by the rollout of Brightree ReSupply and SNAP technology.
  • The company is actively investing in technology, including AI and ML, to enhance its digital health ecosystem and improve patient outcomes.
  • ResMed Inc (RMD) is expanding its global reach with the AirSense 11 platform, launching in new markets such as India, and planning further launches throughout 2025.
Negative
  • Foreign currency movements negatively impacted revenue by approximately $2 million in the December quarter, with further impacts expected in Q3.
  • SG&A expenses increased by 9%, driven by higher employee-related costs and marketing expenses, although they improved slightly as a percentage of revenue.
  • R&D expenses also rose by 10%, primarily due to increased employee-related expenses, maintaining a similar percentage of revenue as the previous year.
  • The company faces challenges in scaling home sleep testing and remote setup to accommodate potential new patient inflows, as sleep physicians in the US struggle with capacity.
  • ResMed Inc (RMD) anticipates potential impacts from global economic conditions, including currency fluctuations and tariffs, which could affect future financial performance.
Operator

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call.

My name is Matt and I'll be your operator for today's call.

(Operator Instructions)

Please note that this conference call is being recorded. I would now like to turn the call over to Mike Ott, Senior Manager, Investor Relations.

Thank you. You may begin.

Mike Ott
Resmed Inc - Senior Manager, Investor Relations

Great. Thank you, Matt. Hello, everyone, and welcome to ResMed's second-quarter, fiscal-year 2025 earnings call. We are live webcasting this call and the replay will be available on the Investor Relations section of our website later today.

Our earnings press release and presentation are both available online now. During today's call, we'll discuss several non-GAAP measures that we believe provide helpful information for investors. This information is not intended to be considered in isolation or as a substitute for the GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot